Lifestyle Intervention in Overweight/Obese Chronic Low Back Pain (CLBP) Patients: an International Multi-center RCT
Launched by VRIJE UNIVERSITEIT BRUSSEL · Mar 28, 2023
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how a weight loss program, combined with education about pain and targeted exercise, can help people who are overweight or obese and suffer from chronic low back pain (CLBP). The researchers want to see if losing weight and improving health can lead to less pain and better daily functioning. The trial will include adults aged 18 to 65 who have had low back pain for at least three months and have a body mass index (BMI) of 25 or higher. Participants will continue their usual care while taking part in this study.
If you join the trial, you can expect to be randomly assigned to one of two groups: one will receive the weight loss program along with pain education and exercise, while the other will only receive the education and exercise. The study will last for 12 months, and researchers will check in on your pain levels and quality of life during this time. It's important to know that certain individuals, like those with very high BMI or specific medical conditions, may not be eligible to participate. Overall, this trial aims to find effective ways to reduce pain and improve the lives of those dealing with chronic low back pain and overweight or obesity.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults (18 - 65 years)
- • Overweight (BMI ≥ 25 kg/m2) or obese (BMI ≥ 30 kg/m2) women and men.
- • CLBP (n=252), which is defined as nonspecific low back pain for at least 3 months duration, currently seeking care for low back pain and leg pain not ≥ 7 (on a maximum of 10) on a numeric rating scale.
- • Continue usual care 6 weeks prior to (to obtain a steady stat) and during study participation.
- • Depending on the country of inclusion: Native Dutch speaker (for Belgium) or Native German speaker (for Switzerland).
- Exclusion Criteria:
- • Patients with BMI ≥ 40 kg/m² will be excluded as people being morbid obese are eligible to undergo abdominal surgery. Because BMI may not always correspond to the same body fat percentage in different individuals (e.g., athletic types with higher muscle mass may also have BMIs ≥ 25 km/kg²), each participant's body fat percentage will be measured using the TANITA and compared to the body fat percentage reference values. Participants with exceeding BMI but falling into the healthy fat percentage range (which is sex-, age- and ethnicity dependent will be excluded.
- • Pregnant, currently breastfeeding or given birth in preceding year.
- • Currently receiving dietary or exercise interventions or received in the past 6 weeks.
- • Show evidence of specific spinal pathology based on self-report (e.g., hernia, spi-nal stenosis, spondylolisthesis, infection, spinal fracture or malignancy), or a se-vere underlying comorbidity specific diagnoses that interfere with treatment (e.g., diagnosed diabetes, cardiovascular problems, metabolic diseases)
- • Other severe diseases based on current medication intake or being currently treated by a medical doctor for a specific diagnosis, (e.g. diagnosed eating disorders).
- • Ongoing problems or cases with insurance companies regarding their back.
About Vrije Universiteit Brussel
The Vrije Universiteit Brussel (VUB) is a distinguished research university located in Brussels, Belgium, known for its commitment to innovative education and cutting-edge research across various disciplines. As a clinical trial sponsor, VUB actively engages in advancing medical knowledge and improving patient care through rigorous scientific investigations. The university fosters collaborations with healthcare institutions and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements. VUB's research initiatives are driven by a multidisciplinary approach, leveraging expertise from fields such as medicine, health sciences, and biomedical engineering to address pressing health challenges and contribute to the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brussels, , Belgium
Bern, , Switzerland
Patients applied
Trial Officials
Jo Nijs, PhD
Principal Investigator
Vrije Universiteit Brussel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials